Sputnik.az reports that the effectiveness of the Sputnik V coronavirus vaccine, developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, is 91.6%.
Sputnik.az compared Sputnik V with other vaccines, noting that AstraZeneca was effective at 62.1%, Sinopharm at 79.3%, and Sinovac at 50.4%.
The website made a similar claim in another article published a few hours apart on the same day. That article said that the supply of the Sputnik V vaccine could bring Russia and the European Union closer together.
Fakt Yoxla examined whether the claim of Sputnik.az about Sinovac was true.
Vaccination against the COVID-19 virus began in Azerbaijan on January 18.
At a briefing held by the Operational Headquarters under the Cabinet of Ministers on January 16, Teymur Musayev, head of the Health Ministry's department, said that 4 million doses of vaccine had been ordered from Sinovac, of which 2 million doses had already been delivered to the country.
Since the government has so far preferred Sinovac company in importing vaccines, Fakt Yoxla has limited the study to a claim against this company.
The vaccine has been officially registered in Turkey, China, Indonesia, Chile, Brazil, Hong Kong, and the Philippines. However, only a few of these countries - Brazil, Turkey, Indonesia, and Chile - have commented on its effectiveness.
According to information published by Sinovac company on April 3, the effectiveness of the vaccine against symptomatic COVID-19 was 50.65% in Brazil and 91.25% in Turkey.
Euronews reported in March that according to a study by Hacettepe University, the effectiveness of the vaccine in Turkey was 83.5%.
As for Indonesia, the National Agency of Drug and Food Control (BPOM) said the vaccine was 65.3% effective against the disease after clinical trials.
Chile said the Sinovac vaccine was 56.5% effective. This figure is the result of a study by the University of Chile.
Thus, the effectiveness of the vaccine produced by Sinovac varies between 50.65% and 83.5%. According to Reuters, this difference is due to the trial size, patient criteria, target groups, etc.
Fakt Yoxla concludes that the claim of Sputnik.az about Sinovac is a Manipulation of Facts.